Targeted Therapy for Lung Cancer: The Greater Impact in the New Era
|
|
- Ralf Bell
- 8 years ago
- Views:
Transcription
1 Targeted Therapy for Lung Cancer: The Greater Impact in the New Era Fadlo Raja Khuri, MD Professor and Roberto C. Goizueta Chair Department of Hematology & Medical Oncology Deputy Director Winship Cancer Institute Georgia Cancer Coalition Professor Debates and Didactics in Hematology and Medical Oncology Sea Island, Georgia, July 23, 2015
2 Targeted Therapies vs Immunotherapy for Lung Cancers Opportunities to specifically target drivers of oncogene addicted lung cancers Much higher response rates with more durable benefits Readily available and reliable biomarker in genomic testing Far better cost/benefit ratio Better understood mechanisms of resistance
3 Therapeutic Plateau in Metastatic NSCLC? ECOG 1594 Patient Survival (%) Cisplatin/Paclitaxel Cisplatin/Gemcitabine Cisplatin/Docetaxel Carboplatin/Paclitaxel Time (mos) ECOG=Eastern Cooperative Oncology Group. Schiller JH, et al. N Engl J Med. 2002;346:92-98.
4
5 Positions of Mutations Detected in EGFR Tyrosine Kinase Domain in NSCLC EGF ligand binding Tyrosine kinase Autophosphorylation TM K DFG Y Y Y Y Exon: Paez: GXGXXG K R H DFG L L Y Lynch: G719 L858 Pao: Tumor with point mutation (amino acid substitution) Tumor with in-frame deletion Activation loop EGF=endothelial growth factor; TM=transmembrane. Adapted from Pao et al. Proc Natl Acad Sci U S A. 2004;101: Lynch et al. N Engl J Med. 2004;350:2129. Paez et al. Science. 2004;304:1497.
6 IPASS: PFS in EGFR Mutation Positive and Negative Patients EGFR mutation positive EGFR mutation negative Probability of progression-free survival At risk : Gefitinib C / P Gefitinib (n=132) Carboplatin / paclitaxel (n=129) HR (95% CI) = 0.48 (0.36, 0.64) P <.0001 No. events gefitinib, 97 (73.5%) No. events C / P, 111 (86.0%) RR- 71%; 47% Months Probability of progression-free survival Gefitinib (n=91) Carboplatin / paclitaxel (n=85) HR (95% CI) = 2.85 (2.05, 3.98) P <.0001 No. events gefitinib, 88 (96.7%) No. events C / P, 70 (82.4%) RR- 1.1%; 23% Months ITT population Cox analysis with covariates Mok TS, et al. N Eng J Med. 2009;361: Treatment by subgroup interaction test, P <.0001
7 First- Line TKI Therapy in EGFR Mutated NSCLC Randomized Phase III Trials Study IPASS (Mok TS, et al. N Engl J Med. 2009;361: ) WJTOG3405 (Mitsudomi T, et al. Lancet Oncol. 2010; 11: ) Maemondo M, et al. N Engl J Med. 2010; 362: OPTIMAL (Zhou C, et al. Lancet Oncol. 2011;12: ) EURTAC (Rosell R, et al. Lancet Oncol. Jan 25, 2012 [Epub ahead of print].) N Treatment Arm Control Arm 1217 Gefitinib Carboplatin/ Placitaxel 177 (M+) Gefitinib Cisplatin, Docetaxel 230 (M+) Gefitinib Carboplatin, Paclitaxel 165 (M+) Erlotinib Carboplatin/ Gemcitabine 153 (M+) Erlotinib Platinum-based chemotherapy Stage IIIB/IV IIIB/IV Median PFS 5.7 vs 5.8 months (HR for EGFR mutated pts 0.48; HR for nonmutated pts 2.84) 9.2 vs 6.3 months (P < 0.001) IIIB/IV 10.8 vs 5.4 months (HR 0.3, P < ) IIIB/IV 13.6 vs 4.6 months (HR 0.16, P < ) IIIB/IV 9.4 vs 5.2 months (HR, 0.42, P < ) Median OS 18.6 vs 17.3 months (P = NS) 30.5 vs 23.6 months (P = NS) 22.9 vs 18.8 months (P = 0.42) PFS is superior, no survival advantage for first line TKI- effect of cross-over Indication First-line First-line First-line First-line First-line
8 EGFR-TKIs: Secondary Resistance 37 patients re-biopsied at the time of progression 6/18 patients with T790M had other molecular abnormalities 5 patients had SCLC phenotype Sequist L, et al. Sci Transl Med. 2011;3:75ra26.
9 T790M in Acquired Resistance Acquired exon 20 mutation found in >50% of patients with acquired resistance to TKI Increases relative affinity of mutant EGFR for ATP, may also cause steric hindrance to erlotinib T790M More likely to show progression in lungs/pleura Less commonly detected in CNS May have better prognosis than non-t790m Oxnard GR, et al. Clin Cancer Res. 2011;17:
10 Phase I Dose Escalation / Expansion Global Study Design First-line cohorts objective assessment of the safety and tolerability of AZD9291 when given orally as first-line therapy to patients who are treatment-naïve for locally advanced or metastatic EGFRm positive NSCLC Escalation Rolling six design Cohort 1 Cohort 2 Cohort 3 Cohort 4 Cohort 5 20 mg 40 mg 80 mg 160 mg 240 mg Expansion Enrollment by local identification of EGFR mutation followed by central laboratory confirmation (cobas EGFR Mutation Test) or by central laboratory testing alone Positive Positive Positive Positive Positive Negative Negative Negative First-line EGFRm* 80mg Biopsy Tablet First-line EGFRm* 160mg Biopsy T790M cohorts *Prior therapy for advanced NSCLC not permissible in this cohort Data cut-off April 15, 2015 Data from cohorts in grayed out boxes are not included in the analyses reported here Cytology Ramalingam SS, et al. J Clin Oncol. 2015;33(suppl): Abstract 8000.
11 AZD9291: T790M+ (central test; N=138) 20 mg 40 mg 80 mg 160 mg 240 mg Confirmed ORR in patients with centrally tested T790M+ tumours was 61% (78/127; 95% CI 52%, 70%) Disease control rate (CR+PR+SD) was 95% (121/127; 95% CI 90%, 98%) CI, confidence interval; ORR, overall response rate; CR, complete response; PR, partial response; SD, stable disease; D, discontinued *Imputed values for patients who died within 14 weeks (98 days) of start of treatment and had no evaluable target lesion assessments. Patients are eligible for confirmed response if they have two post-baseline RECIST assessments or patients who withdraw/die prior to the second RECIST assessment. Data cut-off 1 Aug 2014 Janne et al, N Engl J Med, 2015
12 Response Rate in First-line Cohorts by Dose D D D D D D Best percentage change from baseline in target lesion D D 80 mg N= mg N=30 D D Total N=60 80 mg 160 mg * D Objective response rate # 63% (95% CI 44, 80) 83% (95% CI 65, 94) 73% (95% CI 60, 84) Disease control rate 93% (95% CI, 78, 99) 100% (95% CI 88, 100) 97% (95% CI 89, 100) Best objective response Complete response # Partial response # Stable disease Progressive disease Population: evaluable for response, data cut-off April 15, 2015 Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST 1.1), programmatically calculated from investigator-recorded tumor measurement *Considered a complete response because target lesion <10mm (lymph node) with complete response in non-target-lesions and no new lesions #Confirmed responses only CI, confidence interval; CR, complete response; D, discontinued; DCR, disease control rate; PR, partial response; SD, stable disease Ramalingam SS, et al. J Clin Oncol. 2015;33(suppl): Abstract 8000.
13 CO-1686: A third-generation EGFR Inhibitor Presented By Lecia Sequist at 2014 ASCO Annual Meeting
14 Best Response to Rociletinib (All Doses) in 256 Centrally Confirmed Tissue T790M+ Patients 100 SLD Change from Baseline (%) mg 625mg 750mg 1000mg Total N ORR (%) DCR (%) ORR, objective response rate; DCR, disease control rate 500mg BID HBr 625mg BID HBr 750mg BID HBr 1000mg BID HBr + Ongoing SLD, sum of longest diameters *3 patients currently have no evaluable baseline lesions per database and are omitted from this analysis 14
15 Acquired Resistance to Rociletinib is Heterogeneous Longitudinal quantitative analyses of EGFR T790M and activating mutations in plasma MGH/Stanford analysis of primary/acquired* rociletinib resistance (N=13) T790-WT SCLC (n=2) T790M-positive NSCLC (n=4) T790-WT NSCLC (n=4) T790Mpositive NSCLC (EGFR- *Acquired resistance = progression after initial tumor shrinkage; primary resistance = PD at first assessment scan Piotrowska Z, et al. Cancer Disc. 2015;5(7): l
16 ALK Fusion Gene Potent oncogenic activity Present in approximately 4-5% of NSCLC More common in Never-smokers Adenocarcinoma Signet ring morphology Soda et al, Nature, 2007; Shaw et al, J Clin Oncol, 2009.
17 Clinical and Demographic Features of Patients With ALK-positive NSCLC Median age Is younger 30% smokers N=149 N = 136 Median (range) age, years 52 (21 86) 52 (29-82) Gender, male/female 49/51 47/53 Race, n (%) White 95 (64) 87 (64) Asian 41 (28) 43 (32) Others 13 (9) 6 (4) Smoking history, n (%) Never smoker 106 (71) 92 (68) Former smoker 42(28) 39 (29) Current smoker 1 (1) 5 (4) Histology, n (%) Adenocarcinoma 144 (97) 130 (96) Squamous 2 (1) 0 (0) Prior treatment regimens, n (%) Other 3 (2) 6 (4) 0 24 (6) 1 47 (33) 2 31 (18) 3 47 (41) 1. Camidge DR, et al. Lancet Oncol. 2012;13: Crino D, et al. J Clin Oncol. 2011;29(suppl. Abstract 7514).
18 Crizotinib: Best Percent Change from Baseline in Target Lesions* % Decrease or increase from baseline Progressive disease Stable disease Partial response Complete response Objective response details (all evaluable patients) N=116** ORR (95% CI) 61% (52, 70) Median response duration Median time to response 48 weeks 8 weeks Disease control rate at 8, 16 weeks 79%, 67% *excludes patients with early death and indeterminate response (n=106) **includes patients with early death and indeterminate response (n=116) Camidge et al, ASCO 2011
19 Mechanisms of Crizotinib Resistance A B Doebele et al. CCR, 2012
20 Best % change from baseline 100 Marked Activity of LDK378 in Patients with Advanced ALK+ NSCLC Best % change from baseline in target lesions LDK mg/day Prior crizotinib Crizotinib- naïve 80 PFS event 100 ORR: 60% in crizotinib-naïve patients and 57% in crizotinib-treated patients
21 Other ALK Inhibitors Alectinib 1 Response rate of > 90% in Crizotinib-naïve patients Activity demonstrated in crizotinib-resistant patients with RR of ~ 50% AP26113 Dual ALK and EGFR inhibitor Active in patients with secondary resistance to ALK 1. Gadgeel et al, WCLC 2013, Abstract O16.06
22 ROS1 Rearrangements in NSCLC TPM3-ROS1 SLC34A2-ROS1 SDC4-ROS1 CD74-ROS1 Present in ~1% of NSCLC cases (also found in some GBMs and cholangiocarcinomas) Enriched in younger never or light smokers with adenocarcinoma histology No overlap with other oncogenic drivers LRIG3-ROS1 EZR-ROS1 ROS1 Bergethon et al., JCO 30(8): , 2012; Takeuchi et al., Nat Med 18(3): , 2012
23 Summary of Tumor Responses in Patients with Advanced ROS1+ NSCLC (N=14*) 100 Decrease or Increase From Baseline (%) PD SD PR CR
24 BRF113928: Study Design Single arm, phase 2, open label NSCLC BRAF V600E mutation N = 20 Stage 1 N = 20 Stage 2 1 line prior tx Dabrafenib 150 mg twice daily Primary objective: Investigator-assessed ORR Secondary objectives: PFS, duration of response, overall survival (OS), safety, tolerability, and population pharmacokinetics Green-Dahlberg 2-stage: H(0) ORR 10% versus H(1) ORR 30% (primary cohort)
25 Maximum Percent Reduction at Time of Best Disease Assessment Maximum Reduction of Sum of Lesion Diameters by Best Confirmed Response for First 20 Patients *** *** *** Best Confirmed Response Partial response Stable disease Progressive disease * ** ** ** Smoking History * ** *** ** Nonsmoker Smoker, 40 pack years Smoker, > 40 pack years * ** * ** * ** ** *
26 BRF113928: Study Design Cohort A (monotherapy) n = 60 Stage IV NSCLC BRAF V600E ECOG 0-2 At least 1 platinum-based chemotherapy Dabrafenib 150mg BID Stage 1 N = 20 Stage 2 N = 20 Expansion N = 20 COMPLETE Reported at ESMO 2014* Cohort A (combination D+T) n = 40 Interim futility analyses Stage IV NSCLC BRAF V600E ECOG tx lines only (at least 1 platinum-based chemotherapy) Dabrafenib 150mg BID Trametinib 2mg once daily Stage 1 N = 20 Stage 2 N = 20 Recruitment stopped if insufficient clinical activity is observed in first 20 subjects ONGOING > Passed futility LSFV 14JAN2015 *Planchard D, et al. Ann Oncol 2014;25(suppl 4):abstract LBA38_PR.
27 Maximum Reduction of Sum of Lesion Diameters By Best Confirmed Response in 2nd Line (N = 24) Maximum Percent Reduction at Time of Best Disease Assessment Best Confirmed Response PR SD PD The median duration of response was not reached
28 Duration of Treatment for All Enrolled Patients in the Interim Analysis (n = 33) * Best Unconfirmed Response Complete Response Partial Response Stable Disease Progressive Disease Not Evaluable Not Available First complete response First partial response Disease progressed Still on study treatment *1 st -line patient (protocol deviation) Treatment Duration (Months)
29 Nivolumab Overall Survival mos mo, (95% CI) Nivolumab n = (7.3, 13.3) Docetaxel n = (5.1, 7.3) 70 # events OS (%) yr OS rate = 42% HR = 0.59 (95% CI: 0.44, 0.79), P = Nivolumab yr OS rate = 24% Docetaxel Time (months) Number of Patients at Risk Nivolumab Docetaxel Symbols represent censored observations
30 Pembrolizumab Potent, humanized monoclonal antibody against PD-1 that prevents PD-1 from binding to its ligands, PD-L1 and PD-L2 Robust antitumor activity and manageable toxicity in multiple tumor types As monotherapy for previously treated and treatment-naive advanced NSCLC in KEYNOTE-001 (n = 495) % ORR, 3.7-month median PFS, 12.0-month median OS 45.2% ORR in patients with PD-L1 expression in 50% of tumor cells 1. Garon EB et al. N Engl J Med. 2015;372:
31 Rationale For Anti PD-1 + Anti CTLA-4 Combination Therapy Complementary mechanisms of action CTLA-4 functions at the activation stage of the anticancer immune response PD-1 functions at the effector stage of the anticancer immune response Preclinical data: synergistic anticancer activity shown in multiple models 1-3 Clinical data: nivolumab (anti PD-1) + ipilimumab has shown significant efficacy and manageable toxicity in advanced melanoma 4,5 and NSCLC 6 1. Curran MA et al. Proc Natl Acad Sci U S A 2010;107: ; 2. Duraiswamy J et al. Cancer Res. 2013;73: ; 3. Selby M et al. J Clin Oncol 2013;31:Abstr 3061; 4. Wolchok JD e al. NEJM. 2013;369: ; 5. Postow MA et al. N Engl J Med. 2015;doi: /NEJMoa ; 6. Antonia SJ et al. J Clin Oncol 2014;32:Abstr 8023.
32 Adverse Events of Special Interest (Any Frequency) Adverse Event, n (%) Total N = 18 Any 6 (33) Adrenal insufficiency (grade 3) 1 (6) Autoimmune thyroiditis (grade 2) 1 (6) Hypothyroidism (grade 1) 1 (6) Hyperthyroidism (grade 2) 1 (6) Maculopapular rash (grade 3) 1 (6) Myasthenia gravis (grade 2) 1 (6) Myocarditis (grade 2) 1 (6) Pneumonitis (grade 1) 1 (6) Thyroiditis (grade 2) 1 (6) Uveitis (grade 2) 1 (6) Analysis cutoff date: March 31, 2015.
33 Best Overall Response (RECIST v1.1, Investigator Review) ORR, n (%) [95% CI] DCR, n (%) [95% CI] Pembro 10 mg/kg Q3W + IPI 1 or 3 mg/kg N = 6 3 (50) [12-88] 6 (100) [54-100] Pembro 2 mg/kg Q3W + IPI 1 mg/kg N = 12 4 (33) [10 65] 9 (75) [43 94] Total N = 18 7 (39) [17 64] 15 (83) [59 96] Best overall response, n (%) CR 1 (17) 0 (0) 1 (6) PR 2 (33) 4 (33) 6 (33) SD 6 weeks 3 (50) 5 (42) 8 (44) PD 0 (0) 3 (25) 3 (17) Analysis cutoff date: March 31, 2015.
34 Change From Baseline in Tumor Size (RECIST v1.1, Investigator Review) Change From Baseline, % Pembrolizumab 10 mg/kg + ipilimumab 1 or 3 mg/kg Pembrolizumab 2 mg/kg + ipilimumab 1 mg/kg 71% of patients showed decrease in target lesion burden Change from baseline was evaluated in patients with 1 postbaseline tumor assessment. Analysis cutoff date: March 31, 2015.
35 Treatment Exposure and Response Duration * * * * * * * CR as best response PR as best response PD as best response Last pembrolizumab dose Treatment ongoing The length of the bars is equivalent to the time to the last disease assessment by the investigator. Analysis cutoff date: March 31, * Time, weeks * * All responses ongoing at the time of data cutoff Response duration: 6+ to 39+ weeks Pembrolizumab 10 mg/kg + ipilimumab 1 or 3 mg/kg Pembrolizumab 2 mg/kg + ipilimumab 1 mg/kg
36 Targeted Therapies vs Immunotherapy for Lung Cancers Opportunities to specifically target drivers of oncogene addicted lung cancers Much higher response rates with more durable benefits Readily available and reliable biomarker in genomic testing Far better cost/benefit ratio Better understood mechanisms of resistance Far lower toxicity than with immunotherapy, especially combined CTLA-4/PD-1 blockade
Non-Small Cell Lung Cancer
Non-Small Cell Lung Cancer in East tasia Chia-Chi (Josh) Lin, MD, PhD 林 家 齊 Director of Phase I Center, e Department of Oncology, National Taiwan University Hospital Clinical Associate Professor, Department
More informationMaintenance therapy in in Metastatic NSCLC. Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai
Maintenance therapy in in Metastatic NSCLC Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai Definition of Maintenance therapy The U.S. National Cancer Institute s
More informationPulmonary and Critical Care Regional Symposium April 25, 2015
Pulmonary and Critical Care Regional Symposium April 25, 2015 2015: Molecular Medicine, Resistance Mutations and Immunotherapy. Keeping Up With The Latest in NSCLC Barbara J. Gitlitz MD Associate Professor
More informationEGFR gene mutations Ex 19 Ex 21 Paez et al, Science 2004
Evolution of knowledge in NSCLC Pao and Girard, Lancet Oncology 2011 Fattori da considerare nella scelta terapeutica del NSCLC nel 2012 Stadio di malattia PS Età Comorbidità Compliance e desiderio del
More informationTargeted therapies and brain metastases in lung cancer patients. Benjamin Besse, MD, PhD. Medical Oncologist. 19 septembre 2014
Targeted therapies and brain metastases in lung cancer patients Benjamin Besse, MD, PhD Medical Oncologist 19 septembre 2014 Targeted therapies and brain mets! Brain mets in NSCLC! Specific targeted therapies!
More informationCancer Treatments Subcommittee of PTAC Meeting held 18 September 2015. (minutes for web publishing)
Cancer Treatments Subcommittee of PTAC Meeting held 18 September 2015 (minutes for web publishing) Cancer Treatments Subcommittee minutes are published in accordance with the Terms of Reference for the
More informationOvarian Cancer and Modern Immunotherapy: Regulatory Strategies for Drug Development
Ovarian Cancer and Modern Immunotherapy: Regulatory Strategies for Drug Development Sanjeeve Bala, MD, MPH Ovarian Cancer Endpoints Workshop FDA White Oak September 3, 2015 Overview Immune agents from
More informationAnti-PD1 Agents: Immunotherapy agents in the treatment of metastatic melanoma. Claire Vines, 2016 Pharm.D. Candidate
+ Anti-PD1 Agents: Immunotherapy agents in the treatment of metastatic melanoma Claire Vines, 2016 Pharm.D. Candidate + Disclosure I have no conflicts of interest to disclose. + Objectives Summarize NCCN
More informationPharmacogenomic markers in EGFR-targeted therapy of lung cancer
Pharmacogenomic markers in EGFR-targeted therapy of lung cancer Rafal Dziadziuszko, MD, PhD University of Colorado Cancer Center, Aurora, CO, USA Medical University of Gdansk, Poland EMEA Workshop on Biomarkers,
More informationWhat is the Optimal Front-Line Treatment for mrcc? Michael B. Atkins, MD Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center
What is the Optimal Front-Line Treatment for mrcc? Michael B. Atkins, MD Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center The Case for Immunotherapy in mrcc 1. Achieves patient s goal 2.
More informationSuccesses and Limitations of Targeted Cancer Therapy in Lung Cancer
Successes and Limitations of Targeted Cancer Therapy in Lung Cancer Kenichi Suda a, b Tetsuya Mitsudomi a a Division of Thoracic Surgery, Department of Surgery, Kinki University Faculty of Medicine, Osaka-Sayama,
More informationTargeted Therapy What the Surgeon Needs to Know
Targeted Therapy What the Surgeon Needs to Know AATS Focus in Thoracic Surgery 2014 David R. Jones, M.D. Professor & Chief, Thoracic Surgery Memorial Sloan Kettering Cancer Center I have no disclosures
More informationUpdate on Targeted Therapies of NSCLC
Update on Targeted Therapies of NSCLC Tanja Cufer, MD, PhD University Clinic Golnik Medical Faculty Ljubljana, Slovenia Bled 2014 1 Systemic Therapy of Advanced NSCLC: Chemotherapy Range Cht improves survival
More informationTargeted agents in lung cancer: EGFR TKI and beyond
Targeted agents in lung cancer: EGFR TKI and beyond David CL Lam, MBBS, PhD, MD, FCCP, FACP, FRCP, FAPSR Clinical Assistant Professor Department of Medicine University of Hong Kong 13 Nov, 2014 The Changing
More informationNieuwe patientenselectie met longcarcinoom als rolmodel voor de medisch oncoloog
Nieuwe patientenselectie met longcarcinoom als rolmodel voor de medisch oncoloog Egbert F. Smit MD PhD Dept. Pulmonary Diseases Vrije Universiteit VU Medical Centre Amsterdam, The Netherlands ASCO 2013
More informationClinical development of AZD9291 in non-small cell lung cancer
Clinical development of AZD9291 in non-small cell lung cancer Rachael Lawrance (AstraZeneca) PSI One Day Meeting: The Innovative, Challenging and Diversified World of Respiratory Disease 13 Nov 2015 Overview
More informationImmuno-Oncology 2015: A New Landscape in Lung Cancer
Immuno-Oncology 2015: A New Landscape in Lung Cancer David R. Spigel, M.D. Lung Cancer Program Director Sarah Cannon Research Institute/Tennessee Oncology, PLLC Nashville, TN Off-Label Use Disclosure(s)
More informationAdditional 50 patients enrolled in KEYNOTE-001 with analyses planned using Merck s proprietary PD-L1 assay at one percent and 50 percent cut points
News Release Media Contacts: Annick Robinson Dominique Quirion Merck NATIONAL Annick.robinson@merck.com dquirion@national.ca 514 428-2890 514 843-2302 Investor Contacts: Justin Holko: (+1 908-423-5088
More informationPiano Generale di Emergenza Presidio Ospedaliero di Livorno Viale Alfieri 36
Aprile 2011 EGFR-TKIs for the treatment of advanced NSCLC with EGFR mutations Piano Generale di Emergenza Presidio Ospedaliero di Livorno Viale Alfieri 36 Federico Cappuzzo Istituto Toscano Tumori Ospedale
More informationThorakale Onkologie. ASCO 2013 Aktuelle Studien TZ Berlin Buch 12.6.2013
Triple negativ Thorakale Onkologie ASCO 2013 Aktuelle Studien TZ Berlin Buch 12.6.2013 Driver Oncogene Mutations in non sq-nsclc Genome Res. 2012 November; 22(11): 2109 2119 8021: Detection of EGFR-activating
More informationTreatment Paradigm in NSCLC Treatment
Treatment Paradigm in NSCLC Treatment Era of Targeted Therapy Aumkhae Sookprasert, MD Medicine Department, KKU Which factors taken to be account in NSCLC treatment? 1. Staging 2. ECOG performance status
More informationALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials)
ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials) 3 Integrated Trials Testing Targeted Therapy in Early Stage Lung Cancer Part of NCI s Precision Medicine Effort in
More informationTrials in Elderly Melanoma Patients (with a focus on immunotherapy)
Trials in Elderly Melanoma Patients (with a focus on immunotherapy) Where we were Immunotherapy Trials: past and present Relevance for real world practice Where we are SIOG October 2012 James Larkin FRCP
More informationNovel Therapies for the Treatment of Non-small Cell Lung Cancer
Novel Therapies for the Treatment of Non-small Cell Lung Cancer Mark A. Socinski, MD Professor of Medicine and Thoracic Surgery Director, Lung Cancer Section, Division of Hematology/Oncology Clinical Associate
More informationPersonalizing Treatment for NSCLC
Educational Objectives At the conclusion of this activity, participants should be able to demonstrate the ability to: Review strategies for molecular evaluation of NSCLC Discuss formulation of treatment
More informationManagement of stage III A-B of NSCLC. Hamed ALHusaini Medical Oncologist
Management of stage III A-B of NSCLC Hamed ALHusaini Medical Oncologist Global incidence, CA cancer J Clin 2011;61:69-90 Stage III NSCLC Includes heterogeneous group of patients with differences in the
More informationASCO 2014: Promise and Progress in the Treatment of Lung Cancer
ASCO 2014: Promise and Progress in the Treatment of Lung Cancer Fadlo Raja Khuri, MD Professor and Chair Department of Hematology & Medical Oncology, Deputy Director Winship Cancer Institute of Emory University
More informationMechanisms of primary/secondary resistance to EGFR inhibitors
UNIVERSITY OF OF TORINO DEPARTMENT OF ONCOLOGY Mechanisms of primary/secondary resistance to EGFR inhibitors Silvia Novello University of Torino Italy Department of Oncology silvia.novello@unito.it www.womengainstlungcancer.eu
More informationPharmacogenomic Approaches. Luis Paz-Ares Hospital Universitario Virgen del Rocio Seville, Spain
Pharmacogenomic Approaches Luis Paz-Ares Hospital Universitario Virgen del Rocio Seville, Spain Pharmacogenetics & Pharmacogenomics Medicine tailored to the individual Genetic information, including the
More informationNational Horizon Scanning Centre. Vandetanib (Zactima) for advanced or metastatic non-small cell lung cancer. December 2007
Vandetanib (Zactima) for advanced or metastatic non-small cell lung cancer December 2007 This technology summary is based on information available at the time of research and a limited literature search.
More informationLung Cancer: More than meets the eye
Lung Cancer Education Program November 23, 2013 Lung Cancer: More than meets the eye Shantanu Banerji MD, FRCPC Presenter Disclosure Faculty: Shantanu Banerji Relationships with commercial interests: Grants/Research
More informationTargeting angiogenesis in NSCLC: Clinical trial update Martin Reck Lung Clinic Grosshansdorf Grosshansdorf, Germany
Targeting angiogenesis in NSCLC: Clinical trial update Martin Reck Lung Clinic Grosshansdorf Grosshansdorf, Germany This presentation was selected by the 15 th World Conference on Lung Cancer Program Committee
More informationHarmesh Naik, MD. Hope Cancer Clinic HOW DO I MANAGE STAGE 4 NSCLC IN 2012: STATE OF THE ART
Harmesh Naik, MD. Hope Cancer Clinic HOW DO I MANAGE STAGE 4 NSCLC IN 2012: STATE OF THE ART Goals Discuss treatment options for stage 4 lung cancer: New and old Discuss new developments in personalized
More informationName of Policy: Molecular Analysis for Targeted Therapy of Non-Small-Cell Lung Cancer (NSCLC)
Name of Policy: Molecular Analysis for Targeted Therapy of Non-Small-Cell Lung Cancer (NSCLC) Policy #: 468 Latest Review Date: October 2015 Category: Laboratory Policy Grade: B Background/Definitions:
More informationLessons learned from gefitinib and crizotinib clinical trials in NSCLC
Lessons learned from gefitinib and crizotinib clinical trials in NSCLC Shun Lu Shanghai Lung Cancer Center Shanghai Chest Hospital affiliated to Jiao Tong University New Era of Cancer Care: Genomic Era
More informationPROSPETTIVE FUTURE NEL TRATTAMENTO. Cinzia Ortega Dipartimento di Oncologia Medica Fondazione del Piemonte per l Oncologia I.R.C.C.S.
PROSPETTIVE FUTURE NEL TRATTAMENTO MEDICO DEL mrcc Cinzia Ortega Dipartimento di Oncologia Medica Fondazione del Piemonte per l Oncologia I.R.C.C.S. Candiolo Future strategies in mrcc Improve therapeutic
More informationIs the third-line chemotherapy feasible for non-small cell lung cancer? A retrospective study
Turkish Journal of Cancer Volume 34, No.1, 2004 19 Is the third-line chemotherapy feasible for non-small cell lung cancer? A retrospective study MUSTAFA ÖZDO AN, MUSTAFA SAMUR, HAKAN BOZCUK, ERKAN ÇOBAN,
More informationCorporate Medical Policy
Corporate Medical Policy Molecular Analysis for Targeted Therapy for Non-Small Cell Lung File Name: Origination: Last CAP Review: Next CAP Review: Last Review: molecular_analysis_for_targeted_therapy_for_non_small_cell_lung_cancer
More informationSummary ID# 13095. Clinical Study Summary: Study H3E-EW-B012
Page 1 Summary ID# 13095 Clinical Study Summary: Study H3E-EW-B012 First-line Treatment of Non-Small Cell Lung Cancer under Routine Conditions: Observational Study on Overall Survival Date summary electronically
More information18.5 Percent Overall Response Rate Observed in Pembrolizumab-Treated Patients with this Aggressive Form of Breast Cancer
News Release Media Contacts: Annick Robinson Investor Contacts: Joseph Romanelli (514) 837-2550 (908) 740-1986 Stephanie Lyttle NATIONAL Public Relations (514) 843-2365 Justin Holko (908) 740-1879 Merck
More informationAdjuvant Therapy Non Small Cell Lung Cancer. Sunil Nagpal MD Director, Thoracic Oncology Jan 30, 2015
Adjuvant Therapy Non Small Cell Lung Cancer Sunil Nagpal MD Director, Thoracic Oncology Jan 30, 2015 No Disclosures Number of studies Studies Per Month 12 10 8 6 4 2 0 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3
More informationMelanoma and Immunotherapy
Melanoma and Immunotherapy Sanjiv S. Agarwala, MD Professor of Medicine Temple University School of Medicine Chief, Oncology & Hematology St. Luke s Cancer Center, Bethlehem, PA The Transformed Landscape
More informationUnderstanding series. new. directions. 1-800-298-2436 LungCancerAlliance.org. A guide for the patient
Understanding series LUNG CANCER: new treatment directions 1-800-298-2436 LungCancerAlliance.org A guide for the patient TABLE OF CONTENTS What s New in lung cancer? Advancements...4 Changes in genes that
More informationMedical Policy Manual. Date of Origin: August 2010. Topic: Molecular Analysis for Targeted Therapy of Non- Small Cell Lung Cancer (NSCLC)
Medical Policy Manual Topic: Molecular Analysis for Targeted Therapy of Non- Small Cell Lung Cancer (NSCLC) Section: Genetic Testing Policy No: 56 Date of Origin: August 2010 Last Reviewed Date: December
More informationNEW CLINICAL RESEARCH OPTIONS IN PANCREATIC CANCER IMMUNOTHERAPY. Alan Melcher Professor of Clinical Oncology and Biotherapy Leeds
NEW CLINICAL RESEARCH OPTIONS IN PANCREATIC CANCER IMMUNOTHERAPY Alan Melcher Professor of Clinical Oncology and Biotherapy Leeds CANCER IMMUNOTHERAPY - Breakthrough of the Year in Science magazine 2013.
More informationCáncer de Pulmón n con Mutación de EGFR: Una Entidad Clínica y Patológica Distinta
Cáncer de Pulmón n con Mutación de EGFR: Una Entidad Clínica y Patológica Distinta Luis Paz-Ares Hospital Universitario Virgen del Rocio Seville, Spain Advanced NSCLC: chemotherapy has reached a therapeutic
More informationCLINICAL POLICY Department: Medical Management Document Name: Opdivo Reference Number: CP.PHAR.121 Effective Date: 07/15
Page: 1 of 6 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted
More informationREPORT ASCO 2011 CHICAG0 : RESPIRATORY ONCOLOGY Johan Vansteenkiste / Christophe Dooms, Univ. Hospital Leuven and Leuven Lung Cancer Group
1 REPORT ASCO 2011 CHICAG0 : RESPIRATORY ONCOLOGY Johan Vansteenkiste / Christophe Dooms, Univ. Hospital Leuven and Leuven Lung Cancer Group 10 MESSAGE HIGHLIGHTS Early stage non-small cell lung cancer
More informationFoundational Issues Related to Immunotherapy and Melanoma
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationPublished Ahead of Print on April 11, 2011 as 10.1200/JCO.2010.31.8923. J Clin Oncol 29. 2011 by American Society of Clinical Oncology
Published Ahead of Print on April 11, 2011 as 10.1200/JCO.2010.31.8923 The latest version is at http://jco.ascopubs.org/cgi/doi/10.1200/jco.2010.31.8923 JOURNAL OF CLINICAL ONCOLOGY A S C O S P E C I A
More informationBreast and Lung Cancer Biomarker Research at ASCO: Changing Treatment Patterns
July 2013 Edition Vol. 7, Issue 7 Breast and Lung Cancer Biomarker Research at ASCO: Changing Treatment Patterns By Julie Katz, MPH, MPhil Biomarkers played a prominent role in the research presented in
More informationCancer Treatments Subcommittee of PTAC Meeting held 2 March 2012. (minutes for web publishing)
Cancer Treatments Subcommittee of PTAC Meeting held 2 March 2012 (minutes for web publishing) Cancer Treatments Subcommittee minutes are published in accordance with the Terms of Reference for the Pharmacology
More informationBackground. t 1/2 of 3.7 4.7 days allows once-daily dosing (1.5 mg) with consistent serum concentration 2,3 No interaction with CYP3A4 inhibitors 4
Abstract No. 4501 Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from a Phase III randomized, open-label, multicenter trial R. Motzer, D.
More informationTreatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost-Effectiveness
Department of Veterans Affairs Health Services Research & Development Service Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost-Effectiveness
More informationStato dell arte e prospettive delle terapie a bersaglio molecolare nel carcinoma polmonare
Stato dell arte e prospettive delle terapie a bersaglio molecolare nel carcinoma polmonare Giorgio V. Scagliotti Università di Torino Dipartimento di scienze cliniche & biologiche giorgio.scagliotti@unito.it
More informationNCCN Non-Small Cell Lung Cancer V.1.2011 Update Meeting 07/09/10
Guideline Page and Request NSCL-3 Stage IA, margins positive delete the recommendation for chemoradiation. Stage IB, IIA, margins positive delete the recommendation for chemoradiation + Stage IIA, Stage
More informationGenomic Medicine The Future of Cancer Care. Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America
Genomic Medicine The Future of Cancer Care Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America Personalized Medicine Personalized health care is a broad term for interventions
More informationGenomic Clinical Trials: NCI Initiatives
Genomic Clinical Trials: NCI Initiatives James H. Doroshow, M.D. Deputy Director for Clinical and Translational Research National Cancer Institute National Cancer Advisory Board Washington, DC December
More informationEmerging Drug List GEFITINIB
Generic (Trade Name): Manufacturer: Gefitinib (Iressa ) formerly referred to as ZD1839 AstraZeneca NO. 52 JANUARY 2004 Indication: Current Regulatory Status: Description: Current Treatment: Cost: Evidence:
More informationSYSTEMIC THERAPY FOR STAGE IV NON-SMALL CELL LUNG CANCER: AMERICAN SOCIETY OF CLINICAL ONCOLOGY CLINICAL PRACTICE GUIDELINE UPDATE
Which patients with stage IV NSCLC should be treated with chemotherapy? NSCLC with nonsquamous cell carcinoma, negative or unknown EGFR-sensitizing mutation and ALK gene rearrangement status, and PS 0-1
More informationNON-SMALL CELL LUNG CANCER STAGE IV
NON-SMALL CELL LUNG CANCER STAGE IV Effective Date: November, 2013 The recommendations contained in this guideline are a consensus of the Alberta Provincial Thoracic Tumour Team synthesis of currently
More informationCurrent Progress for Non-Small Cell Lung Cancer Treatment
Chemotherapy : Mechanisms of Action Current Progress for Non-Small Cell Lung Cancer Treatment Topo inhibitors Alkylators CHR Tubulin active agents Topo I,II Pt Wen-Pin Su, M.D./ Prof. Wu-Chou Su National
More informationTreatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost Effectiveness
Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost Effectiveness Investigators: Paul G. Shekelle, MD, PhD, Director Alicia R. Maher, MD Clinical
More informationPOLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY
Original Issue Date (Created): 9/1/2011 Most Recent Review Date (Revised): 1/27/2015 Effective Date: 11/2/2015 POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS
More informationTargeterbare mutationer / biomarkører Status og udfordringer for patologien
Targeterbare mutationer / biomarkører Status og udfordringer for patologien Birgit Guldhammer Skov overlæge, dr.med. Patologi afdelingen Rigshospitalet Biomarkers lung cancer Last 3-5 years More and more
More informationPfizer Forms Global Alliance with Merck KGaA, Darmstadt, Germany to Accelerate Presence in Immuno-Oncology. November 17, 2014
Pfizer Forms Global Alliance with Merck KGaA, Darmstadt, Germany to Accelerate Presence in Immuno-Oncology November 17, 2014 Forward-looking statements Our discussions during this conference call will
More informationSur les nouveaux médicaments et les perspectives qu ils offrent (traitement à la carte et survie longue)
Sur les nouveaux médicaments et les perspectives qu ils offrent (traitement à la carte et survie longue) Professeur Jean Trédaniel Unité de cancérologie thoracique Hôpital Saint-Louis Comparison of Four
More information( targeted therapy ) ( oncogenesis ) ( epidermal. growth factor receptor tyrosine kinase inhibitor EGFR-TKI ) ( epidermal growth
2008 19 8-13 growth factor receptor tyrosine kinase inhibitor EGFR-TKI ) ( targeted therapy ) ( oncogenesis ) ( epidermal factor receptor monoclonal antibody EGFR-moAb ) growth factor monoclonal antibody
More informationMAINTENANCE CHEMOTHERAPY
1 MAINTENANCE CHEMOTHERAPY FOR ADVANCED NSCLC Dr.M.V.Nagarjuna OBJECTIVES OF THIS SEMINAR 1. Definitions 2. Switch maintenance 3. Continuation Maintenance 4. Immunotherapy as maintenance 5. Conclusions
More informationEvaluating the Efficiency of Targeted Designs for Randomized Clinical Trials
Vol. 0, 6759 6763, October 5, 004 Clinical Cancer Research 6759 Perspective Evaluating the Efficiency of Targeted Designs for Randomized Clinical Trials Richard Simon and Aboubakar Maitournam Biometric
More informationThe role of PARP inhibitors in high grade serous ovarian cancers
The role of PARP inhibitors in high grade serous ovarian cancers Jonathan Ledermann UCL Cancer Institute University College London ANZGOG-ASGO, Canberra, March 214 Cancer Research UK UCL Centre DNA Repair
More informationVan Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.
Efficacy Results from the ToGA Trial: A Phase III Study of Trastuzumab Added to Standard Chemotherapy in First-Line HER2- Positive Advanced Gastric Cancer Van Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.
More informationPredictive Biomarkers for PD1 Pathway Inhibitor Immunotherapy
Predictive Biomarkers for PD1 Pathway Inhibitor Immunotherapy Michael B. Atkins, M.D. Deputy Director Georgetown-Lombardi Comprehensive Cancer Center Michael Atkins, MD Consulting Fees (e.g., advisory
More informationCâncer de Pulmão. Benefício e emprego das novas drogas. XIV Congresso da Sociedade Brasileira de Radioterapia
+ Câncer de Pulmão Benefício e emprego das novas drogas XIV Congresso da Sociedade Brasileira de Radioterapia Maikol Kurahashi, MD. Oncologia Clínica Hospital Santa Casa de Curitiba Declaração de conflitos
More informationInnovation: Present Meets Future
Innovation: Present Meets Future SOCIAL INNOVATION Leading Innovation in the Cooperative Group Setting Craig Nichols, M.D. BEST OF SWOG Barlogie-Salmon Myeloma Committee Robert Z. Orlowski, M.D., Ph.D.
More informationThird-line or fourth-line chemotherapy in non-small-cell lung cancer patients with relatively good performance status
Available online at www.sciencedirect.com Journal of the Chinese Medical Association 74 (2011) 209e214 Original Article Third-line or fourth-line chemotherapy in non-small-cell lung cancer patients with
More informationProposal for Tyrosine Kinase Inhibitors for Non Small Cell Lung Cancer
31 May 2012 Proposal for Tyrosine Kinase Inhibitors for Non Small Cell Lung Cancer PHARMAC is seeking feedback on a proposal to: fund gefitinib (Iressa) as a first line treatment for patients with locally
More informationAdvancing Personalized Therapy for Advanced Non-Small Cell Lung Cancer
GUIDING THE WAY White Paper Advancing Personalized Therapy for Advanced Non-Small Cell Lung Cancer is a serum proteomic test for patients with advanced non-small cell lung cancer that helps healthcare
More informationJanuary 2013 LONDON CANCER NEW DRUGS GROUP RAPID REVIEW. Summary. Contents
LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Paclitaxel albumin (Abraxane ) as a substitute for docetaxel/paclitaxel for cancer Paclitaxel albumin (Abraxane ) as a substitute for docetaxel/ paclitaxel for
More informationPrognostic and Predictive Factors in Oncology. Mustafa Benekli, M.D.
Prognostic and Predictive Factors in Oncology Mustafa Benekli, M.D. NCI Definitions ESMO Course -Essentials of Medical Oncology -Istanbul 2 Prognostic factor: NCI Definition A situation or condition, or
More informationNon Small Cell Lung Cancer: Scientific Discoveries and the Pursuit of Progress
Non Small Cell Lung Cancer: Scientific Discoveries and the Pursuit of Progress Lung Cancer Accounts for 14% of All New Cancer Diagnoses in the United States 1 Lung cancer is the second most common malignancy
More informationPreliminary Results from a Phase 2 Study of ARQ 197 in Patients with Microphthalmia Transcription Factor Family (MiT) Associated Tumors
Preliminary Results from a Phase 2 Study of ARQ 197 in Patients with Microphthalmia Transcription Factor Family (MiT) Associated Tumors John Goldberg 1 *, George Demetri 2, Edwin Choy 3, Lee Rosen 4, Alberto
More informationOI PARP ΑΝΑΣΤΟΛΕΙΣ ΣΤΟΝ ΚΑΡΚΙΝΟ ΤΟΥ ΜΑΣΤΟΥ ΝΙΚΟΛΑΙΔΗ ΑΔΑΜΑΝΤΙΑ ΠΑΘΟΛΟΓΟΣ-ΟΓΚΟΛΟΓΟΣ Β ΟΓΚΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ ΝΟΣ. ΜΗΤΕΡΑ
OI PARP ΑΝΑΣΤΟΛΕΙΣ ΣΤΟΝ ΚΑΡΚΙΝΟ ΤΟΥ ΜΑΣΤΟΥ ΝΙΚΟΛΑΙΔΗ ΑΔΑΜΑΝΤΙΑ ΠΑΘΟΛΟΓΟΣ-ΟΓΚΟΛΟΓΟΣ Β ΟΓΚΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ ΝΟΣ. ΜΗΤΕΡΑ Study Overview Inhibition of poly(adenosine diphosphate [ADP]-ribose) polymerase
More informationThe EGFR mutation and precision therapy for lung cancer
for lung cancer Outcomes in advanced lung cancer have seen meaningful improvement in the past decade thanks to new precision drug therapies. Because tumors usually develop resistance to the drugs, scientists
More informationWhat is the optimal sequence of anti-her2 therapy in metastatic breast cancer?
What is the optimal sequence of anti-her2 therapy in metastatic breast cancer? David Miles Mount Vernon Cancer Centre Northwood Middlesex UKBCM mee)ng: London 2013 Herceptin plus a taxoid extends survival
More informationGemcitabine, Paclitaxel, and Trastuzumab in Metastatic Breast Cancer
Gemcitabine, Paclitaxel, and Trastuzumab in Metastatic Breast Cancer Review Article [1] December 01, 2003 By George W. Sledge, Jr, MD [2] Gemcitabine (Gemzar) and paclitaxel show good activity as single
More informationImmunotherapy for High-Risk and Metastatic Melanoma
Immunotherapy for High-Risk and Metastatic Melanoma Timothy M. Kuzel, MD Professor of Medicine and Dermatology Feinberg School of Medicine Northwestern University Chicago ICLIO 1 st Annual National Conference
More informationNew Trends & Current Research in the Treatment of Lung Cancer, Pt. II
New Trends & Current esearch in the Treatment of Lung Cancer, Pt. II Howard (Jack) West, MD President & CEO, GACE Medical Director, Thoracic Oncology Program Swedish Cancer Institute Seattle, WA Cancer
More informationKRAS Mutation Analysis in Non-Small Cell Lung Cancer (NSCLC) Original Policy Date
MP 2.04.43 KRAS Mutation Analysis in Non-Small Cell Lung Cancer (NSCLC) Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed with literature search/12:2013
More informationTailoring Treatment Plans to Improve Outcomes in the Management of NSCLC
Tailoring Treatment Plans to Improve Outcomes in the Management of NSCLC Martin J. Edelman, MD 1 Educational Objectives Review efficacy and safety data for current and emerging targeted agents and chemotherapy
More informationASCO 12. PD-1 Immunotherapy Makes a Splash at ASCO
PD-1 Immunotherapy Makes a Splash at ASCO By Gregory R. Wolfe, PhD Epigenetic variation and genetic instability in tumor cells yield a variety of tumor antigens that the immune system can recognize to
More informationKanıt: Klinik çalışmalarda ZYTIGA
mkdpk de Sonunda Gerçek İlerleme! Kanıt: Klinik çalışmalarda ZYTIGA Dr. Sevil Bavbek 5. Türk Tıbbi Onkoloji Kongresi Mart 214, Antalya Endocrine therapies Adrenals Testis Abiraterone Orteronel Androgen
More informationNew Treatment Options for Breast Cancer
New Treatment Options for Breast Cancer Brandon Vakiner, PharmD., BCOP Clinical Pharmacy Specialist - Oncology The University of Iowa Hospitals and Clinics Assistant Professor (Clinical) University of
More informationROLE OF RADIATION THERAPY FOR RESECTABLE LUNG CANCER
AFA 08958 From Bench to Bedside From KK DT1 10/27/2015 12:04 PM 01 ROLE OF RADIATION THERAPY FOR RESECTABLE LUNG CANCER Hak Choy, MD University of Texas Southwestern Medical Center Dallas, Texas, USA Orchestrating
More informationSEARCH METHODOLOGY SEARCH STRATEGY #1 (SYSTEMATIC REVIEWS): PubMed 1966-3/16/2012 Cochrane Database of Systematic Reviews All years
Appendix A. Search Strategy for Systematic Reviews and Cost-Effectiveness Analyses (Search #1) TREATMENT OF METASTATIC NON-SMALL-CELL LUNG CANCER SEARCH METHODOLOGY SEARCH STRATEGY #1 (SYSTEMATIC REVIEWS):
More informationShifting the Paradigm for Maintenance Therapy for Non small-cell Lung Cancer
J Hong Kong Col Radiol. 2010;13(Suppl):S16-21 ORIGINAL ARTICLE Shifting the Paradigm for Maintenance Therapy for Non small-cell Lung Cancer VHF Lee Department of Clinical Oncology, Queen Mary Hospital,
More informationMEDICAL POLICY EFFECTIVE DATE: 12/20/07 REVISED DATE: 12/18/08, 12/17/09, 02/17/11, 12/15/11, 12/20/12, 12/19/13, 02/19/15
MEDICAL POLICY SUBJECT: GENOTYPING - EPIDERMAL GROWTH PAGE: 1 OF: 6 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. If a commercial product, including
More informationA clinicians view on NGS of (lung) cancer
A clinicians view on NGS of (lung) cancer oliver.gautschi@onkologie.ch 14.1.2015 Predictive Role of Biomarkers for Lung Cancer Therapy Chemotherapy: not confirmed Anti-Angiogenic-Therapy: not confirmed
More informationFuture Directions in Clinical Research. Karen Kelly, MD Associate Director for Clinical Research UC Davis Cancer Center
Future Directions in Clinical Research Karen Kelly, MD Associate Director for Clinical Research UC Davis Cancer Center Outline 1. Status of Cancer Treatment 2. Overview of Clinical Research at UCDCC 3.
More informationTreatment of Metastatic Breast Cancer: Endocrine Therapies. Robert W. Carlson, M.D. Professor of Medicine Stanford University
Treatment of Metastatic Breast Cancer: Endocrine Therapies Robert W. Carlson, M.D. Professor of Medicine Stanford University MDACC Experience with FAC in Chemotherapy-Naive MBC Greenberg et al, J Clin
More information